What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way
This article was originally published in The Rose Sheet
Executive Summary
A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position
You may also be interested in...
Warnings In 2019, AERs In 2009: Touchstones Toward Homeopathic Guidance
Priority enforcement areas listed in draft guidance note delivery formats other than oral and topical, such as nasal gel product that was early alarm in FDA's evaluation of safety and efficacy across homeopathic market. Recent warnings also noted in revised draft.
Commissioner, Chief Counsel See Wiggle Room In FDA's Legal Powers
Putting FDA's aggressive enforcement plan into action will require more creativity on the part of agency lawyers, according to FDA's commissioner and chief counsel
Commissioner, Chief Counsel See Wiggle Room In FDA's Legal Powers
Putting FDA's aggressive enforcement plan into action will require more creativity on the part of agency lawyers, according to FDA's commissioner and chief counsel